Tobacco Parity Tax Condition for Smoking, Cigarette

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Fralin Biomedical Research Institute, Roanoke, VA
Smoking, Cigarette
Tobacco Parity Tax Condition - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study how different taxes on tobacco products affects what people buy. The Tobacco Parity Tax Condition is a medication that is used to treat smoking and cigarettes. This medication has been previously approved by the FDA for a different condition. No patients in this trial will receive a placebo.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Smoking, Cigarette

Study Objectives

3 Primary · 0 Secondary · Reporting Duration: 1 day

1 day
Poly-tobacco purchasing
Quantity of Tobacco Products Purchased in the High-Tax Tier - Product demand (intensity and elasticity)
Quantity of Tobacco Products Purchased in the Medium- and No-tax tiers - Product substitution (intensity and slope)

Trial Safety

Safety Progress

1 of 3

Other trials for Smoking, Cigarette

Trial Design

4 Treatment Groups

Cigarette smokers - Harm-Reduction
1 of 4
Cigarette smokers - Tobacco Parity
1 of 4
Cigarette smokers - Nicotine-Content
1 of 4
Cigarette smokers - Modified Risk Tobacco Products (MRTP)
1 of 4
Experimental Treatment

280 Total Participants · 4 Treatment Groups

Primary Treatment: Tobacco Parity Tax Condition · No Placebo Group · N/A

Cigarette smokers - Harm-ReductionExperimental Group · 2 Interventions: Market Price Condition (control), Harm-Reduction Tax Condition · Intervention Types: Behavioral, Behavioral
Cigarette smokers - Tobacco ParityExperimental Group · 2 Interventions: Market Price Condition (control), Tobacco Parity Tax Condition · Intervention Types: Behavioral, Behavioral
Cigarette smokers - Nicotine-ContentExperimental Group · 2 Interventions: Market Price Condition (control), Nicotine-Content Tax Condition · Intervention Types: Behavioral, Behavioral
Cigarette smokers - Modified Risk Tobacco Products (MRTP)Experimental Group · 2 Interventions: Market Price Condition (control), Modified Risk Tobacco Product (MRTP) Tax Condition · Intervention Types: Behavioral, Behavioral

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 1 day
Closest Location: Fralin Biomedical Research Institute · Roanoke, VA
Photo of virginia 1Photo of virginia 2Photo of virginia 3
2021First Recorded Clinical Trial
2 TrialsResearching Smoking, Cigarette
3 CompletedClinical Trials

Who is running the clinical trial?

Roswell Park Cancer InstituteOTHER
374 Previous Clinical Trials
29,365 Total Patients Enrolled
2 Trials studying Smoking, Cigarette
246 Patients Enrolled for Smoking, Cigarette
Virginia Polytechnic Institute and State UniversityLead Sponsor
108 Previous Clinical Trials
25,254 Total Patients Enrolled
4 Trials studying Smoking, Cigarette
469 Patients Enrolled for Smoking, Cigarette
Warren K Bickel, Ph.D.Principal InvestigatorFralin Biomedical Research Institute at VTC
4 Previous Clinical Trials
629 Total Patients Enrolled
2 Trials studying Smoking, Cigarette
152 Patients Enrolled for Smoking, Cigarette

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
A breath carbon monoxide sample ≥ 8 ppm is required.
You smoke at least 5 cigarettes daily.\n
Use other tobacco products less than weekly.
You have provided informed consent to be tested for HIV.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.